Dissolving microneedles (DMN) supplemented with therapeutic molecules have been developed to enhance transdermal delivery efficiency of topically applied drugs in a minimally invasive manner. However, the dose of the drugs in DMN system is limited owing to the low solubility of drug. In fact, although triamcinolone acetonide (TA) is one of the most widely prescribed drugs for relieving atopic dermatitis (AD), its poor dissolving nature makes it difficult to design and fabricate DMN containing therapeutic dosage of TA. In this study, TA suspension is introduced to encapsulate therapeutic dosage of TA. Sonication and composition optimization of polymers is key to fabricate high dose TA–DMN to induce particle size reduction and dispersion stability of suspension, respectively. After confirming the physical performance of TA–DMN using the selected formulation in vitro, the anti-inflammatory effects of TA–DMN are evaluated in vivo using a mouse model affected with skin inflammation to mimic AD in humans. Herein, high-dose TA–DMN is presented as a candidate agent for relieving AD and, furthermore, for wide application in the treatment of skin inflammatory diseases in which high-dose steroid drugs are required.
Bibliographical noteFunding Information:
M.J. and B.M.K. contributed equally to this work. This work was supported in-part by Brain Korea 21 (BK21) PLUS program and Technology development Program (S2641709) funded by the Ministry of SMEs and Startups (MSS, Korea).
© 2021 Wiley-VCH GmbH
All Science Journal Classification (ASJC) codes
- Biomedical Engineering
- Pharmaceutical Science